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Abstract
Point mutations in LRRK2 cause autosomal dominant Parkinson’s disease. Despite extensive efforts to determine the
mechanism of cell death in patients with LRRK2 mutations, the aetiology of LRRK2 PD is not well understood. To examine
possible alterations in gene expression linked to the presence of LRRK2 mutations, we carried out a case versus control
analysis of global gene expression in three systems: fibroblasts isolated from LRRK2 mutation carriers and healthy, non-
mutation carrying controls; brain tissue from G2019S mutation carriers and controls; and HEK293 inducible LRRK2 wild type
and mutant cell lines. No significant alteration in gene expression was found in these systems following correction for
multiple testing. These data suggest that any alterations in basal gene expression in fibroblasts or cell lines containing
mutations in LRRK2 are likely to be quantitatively small. This work suggests that LRRK2 is unlikely to play a direct role in
modulation of gene expression, although it remains possible that this protein can influence mRNA expression under
pathogenic cicumstances.
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Introduction
Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the
most common Mendelian genetic cause of Parkinson’s disease
(PD) currently identified [1]. Additionally, variation at this locus
has recently been implicated as a risk factor for sporadic PD in
two genome wide association studies [2,3]. Although the
function of LRRK2 is unknown, the presence of a kinase
domain, a GTPase domain and protein/protein interaction
domains within its open reading frame has led to suggestions
that it could act as a signaling node within cells, with the
protein/protein interaction regions functioning as scaffolding
areas to recruit binding partners and substrates to an active
complex [4,5]. LRRK2 has been implicated in a number of
signaling pathways including ERK signaling and the mTOR
pathway [4,6,7]. It is likely that if LRRK2 does act in this
manner, then alterations in the activity of this protein would
result in changes in signaling pathways leading to downstream
shifts in gene expression.
In addition, a recent study has suggested that pathogenic forms
of LRRK2 bind directly to the miRNA processing enzyme
Argonaute and thus influence mRNA levels in a Drosophila model
of LRRK2 disease [8]. Because mammalian miRNAs potently
reduce mRNA levels [9], the prediction from the Drosophila data
would be that steady state mRNA levels of miRNA targets are
altered in the presence of mutant LRRK2. To test whether
mutations in LRRK2 cause an alteration in basal gene expression
we have examined the impact of mutations in three contexts:
fibroblast cells cultured from PD patients carrying mutations in
LRRK2 (including the R1441G, Y1699C and G2019S muta-
tions), brain tissue from 5 patients carrying the G2019S mutation
compared to idiopathic PD and control brain tissue [10], and
HEK293T cells stably transfected with a plasmid allowing
inducible expression of LRRK2 with or without the R1441C
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mutation. We have compared global gene expression in these




Fibroblast cultures were isolated from PD patients with LRRK2
mutations and healthy controls (summarised in table 1) following
approval of the study by the ethics board of the Royal Free Hospital,
London, UK and informed written consent from the individuals
concerned. Skin punch biopsies (forearm) were cultured in 5 cm2
sterile Petri dishes at 37uC in 5% CO2 in 2 ml DMEM
(supplemented with 10% Fetal Bovine Serum and 1% Penicillin/
Streptomycin solution) until fibroblasts were seen to migrate from
the skin explants [11]. Media volume was increased by 0.5 ml every
2 days. When plates were confluent, fibroblasts were lifted from
dishes by trypsinising with TrypLE (Invitrogen) and transferred to
10 cm2 dishes for culturing. Samples were designated anonymous
identifiers following collection. For collection of RNA, cells were
plated in 10 cm plates at equivalent passage number (n=7) and at
equal density. Following 24 hours growth, RNAwas extracted using
the RNeasy kit (Qiagen) and RNA quality ascertained prior to
microarray analysis using RIN analysis (Agilent). Western blot
analysis of endogenous LRRK2 expression was carried out by
immunoblotting following BCA assay (Pierce, as per manufacturers
instructions), with 10 mg of lysate loaded onto 4–12% Bis Tris gels
(Invitrogen) following denaturation in 4x sample buffer (Invitrogen)
supplemented with 5% b-Mercaptoethanol (Sigma). Proteins were
transferred to PVDF membrane (Millipore) and membranes
blocked with 5% milk solution in Phosphate buffered saline for
1 hour prior to probing with primary (90minutes) and secondary
(60minutes) antibodies. For LRRK2, rabbit monoclonal MJFF2
(Epitomics – see http://www.pdonlineresearch.org/discussions/
lrrk2-antibodies for characterisation of these antibodies) was used
at a 1:1000 dilution, for b Actin mouse monoclonal AC-74 (Sigma)
was used at a 1:5000 dilution. HRP secondary antibodies were used
at a dilution of 1:2000 and 1:10000 for LRRK2 (rabbit) and b Actin
(mouse) respectively. Membranes were washed three times in PBS
supplemented with 1% tween, and exposed to Supersignal ECL
substrate (Pierce). Membranes were exposed to Kodak biomax film
and developed on a Fujifilm developer as per manufacturers
instructions.
HEK293t LRRK2 expression
Flp-In-TRex-LRRK2 293 inducible cell lines [12] were grown
in DMEM with 10%FBS, Pen/Strep, Blasticidin (15 ug/ml final
conc.), Hygromycin (100 ug/ml final conc.). To induce LRRK2
protein expression, Doxycyclin (1 ug/ml final conc) was added to
growth medium for 24–48 hours. LRRK2 expression was detected
using mouse V5 Ab (Invitrogen) against V5 tag for Western blot
and/or ICC. For Western Blotting and Illumina assay, inducible
LRRK2 cells were seeded at 0.96106 cells/well in 6-well plates.
Cells were induced with Doxycyclin and harvested at different
time points with either 0.5 ml Trizol for RNA extraction or PBS
for immunoblot analysis as described above. Expressed LRRK2
was demonstrated to possess kinase activity as previously described
[13,14].
Brain samples
Occipital cortex samples were obtained from the Queen
Square Brain bank (four G2019S samples and idiopathic PD
control samples) and Sun Health brain bank (one G2019S
sample and 36 neuropathologically examined control samples)
[15]. Details of the brain samples used in this study are
summarised in table 2. Samples from both sites had fully
informed consent for retrieval and were authorized for ethically
approved scientific investigation (Research Ethics Committee
number 10/H0716/3).
Human oligonucleotide arrays
Illumina HumanWG-6 and HumanHT-12, and Affymetrix
Exon 1.0 ST Arrays were used according to manufacturer’s
instructions as previously described [16]. Briefly, 500 ng of total
RNA was processed for each sample and quality control using
RNA integrity number (RIN) performed prior to analysis [17].
Expression data was subjected to quantile normalization and
differential expression values calculated on sets of biological
replicates. The threshold for significance for individual genes was
set at +/21.5 fold expression between conditions and P,0.05.
Cluster analyses were derived using the Illumina Beadstudio
software suite. Expression data from this study are MIAME
compliant and have been deposited in the GEO database
(accession number GSE25580).
Results
We compared gene expression in three systems: an inducible
HEK cell model, patient fibroblasts and patient brain samples for
wild type and mutant LRRK2. To confirm expression of LRRK2
in these systems, we carried out western blot analysis using anti-V5
and anti-LRRK2 antibodies for the HEK cells and fibroblasts/
brains samples respectively (Figure 1). In the HEK cells, basal
expression of LRRK2 was low but was increased after induction
within 24–48 hours. Expression levels were similar in both WT
Table 1. Patient and control fibroblast samples used in this
study.






Table 2. Mutant and idiopathic PD occipital cortex samples
used in this study.
Case Age at death Sex Pathology Post mortem delay
G2019S 1 84 F Limbic 32.2
G2019S 2 80 F Limbic 44.4
G2019S 3 81 F Limbic 15
G2019S 4 72 F Limbic 24.55
G2019S 5 85 M Limbic 2
IPD 1 78 F Neocortical 60.3
IPD 2 73 F Neocortical 29
IPD 3 84 F Limbic 30
IPD 4 77 M Limbic 41
IPD 5 85 M limbic 49
doi:10.1371/journal.pone.0022489.t002
Global Gene Expression Analysis of LRRK2 Mutants
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and R1441C lines (Figure 1A and 1B). We also confirmed
expression of WT and mutant (G2019S and Y1699C) LRRK2 in
fibroblast samples (Figure 1C), which again showed similar levels
of expression. Finally, we assessed LRRK2 protein levels in
occipital cortex (Figure 1D), demonstrating expression of full
length LRRK2.
Having confirmed the expression of LRRK2 at the protein level
in these systems, we carried out genome wide expression analysis.
In the HEK cells we compared each cell line induced for 12 h or
24 h to its uninduced controls; no differences in gene expression
were seen in either WT or R1441C expressing cells (Figure 2A–D).
Similarly, no differences in gene expression were seen in fibroblast
cell lines with heterozygous mutant (G2019S) LRRK2 compared
to wild type controls (Figure 2E).
We also examined gene expression in brains of LRRK2 carriers
compared to controls and to idiopathic PD (Figure 2F–H). For this
series of experiments, we took tissue from the occipital cortex,
where LRRK2 is expressed but where there is little evidence of the
disease process as Lewy bodies are rarely formed here and there is
no cell loss [18,19]. Therefore, the aim of this analysis was to
isolate the effects of LRRK2 from the disease process in the
relevant tissue of human brain. Supporting the assumption that
the occipital cortex is largely spared from the disease process,
idiopathic PD cases showed no difference in gene expression
compared to neurologically normal controls in this brain region
(Figure 2H). However, as in the cell line analyses, there was no
effect of LRRK2 mutation on gene expression compared to either
neurologically normal controls or idiopathic PD cases (Figure 2F
and G).
We considered that simply looking for genes whose steady state
expression might miss more subtle patterns in the data and
therefore examined overall gene expression by unsupervised
hierarchical clustering (Figure 3). Samples did not separate by
genotype, again suggesting that there is no significant or consistent
difference between the mutant and wild type cells.
Discussion
This study assessed a series of patient fibroblast cells
harbouring mutations in LRRK2, brain samples from G2019S
carriers and a cell line system over-expressing LRRK2 wild type
and mutant transgenes for alterations in gene expression due to
the presence of mutant LRRK2. Overall, our data show that any
differences in gene expression are lower than the relatively
modest cutoffs (1.5 fold, p,0.05 after correction for multiple
testing) used. In turn, this suggests that mutant LRRK2 does not
elicit large changes in steady state mRNA levels within the cell
under normal growth conditions. This is in contrast to a recent
publication studying a series of mononuclear cells carrying the
G2019S mutation [20] and data from Drosophila and a HEK cell
model [8]. There are a number of possible reasons for the
divergence in our data from those in these studies. With regard to
the former, our cellular studies have been carried out on cultured
cells in a monolayer, rather than primary cells in a suspension,
and both fibroblasts and HEK cells represent a significantly
different cell type to mononuclear cells. Focussing on the
relevance of these systems to the biology of LRRK2, it is notable
that both cell lines carrying plasmids allowing the inducible
expression of LRRK2 and patient fibroblast samples have been
used as model systems for examining the aberrant behaviour of
mutant LRRK2 [8,21]. The recent report of induced pluripotent
stem cells (iPSCs) from a patient carrying a G2019S mutation
offers a model system closer to the human brain for analysing
gene expression alterations due to mutations in LRRK2 [22]. To
date, however, it has not been possible to carry out gene
expression analyses from multiple replicates of iPSC lines
generated from multiple independent LRRK2 mutation carriers,
a key requirement if changes in expression are to be detected and
ascertained as significantly correlated with mutant LRRK2
alleles. To follow up on our analysis of LRRK2 mutations in
model systems used to assess the biology of LRRK2, we
examined the impact of mutant LRRK2 in a disease setting by
carrying out a case control comparison of brain tissue from
patients carrying mutations in LRRK2, idiopathic patient brain
material and control samples derived from the Queen Square and
Sun Health brain banks. Similar to our data from cellular
analyses, no impact of mutations upon expression was observed
once correction for multiple comparisons had been carried out. It
should be noted that analysis of brain expression was limited by
the small number of G2019S brain samples available for mRNA
extraction, an issue that is also reflected in the number of
pathological reports for LRRK2 cases [19].
Our results do not exclude the possibility that gene expression
can be differentially altered by mutations in LRRK2 under
conditions of stress, for example under starvation conditions,
oxidative challenge or widespread cell loss [4]. Several recent
papers have highlighted a potential role for LRRK2 in stress
response via the mTOR pathway, and it is plausible that LRRK2
Figure 1. LRRK2 expression in inducible HEK cell lines and
primary fibroblast cultures. (A) Induction of LRRK2 expression
following exposure of cells to Doxycyclin as measured by immuno-
blotting for V5 epitope (B) Normalised protein expression of wildtype
and R1441C plotted over time (C) Western blot analysis of endogenous
LRRK2 expression in representative mutant and wild type fibroblast
lines (D) Western blot analysis of LRRK2 in human occipital cortex.
doi:10.1371/journal.pone.0022489.g001
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exerts an influence on gene expression following activation in
response to cellular stress. With regard to alterations due to
miRNA regulation, our data demonstrates no overall impact on
mRNA levels. This does not exclude translational regulation as a
mechanism through which a putative LRRK2 miRNA pathway
could operate, although the recent publication by Guo et al
emphasizes that miRNAs in mammalian cells predominantly
function by directly impacting on mRNA levels rather than by
premature translation termination or inhibiting ribosome forma-
tion or binding [9].
In summary, our data provides evidence from two independent
cellular model systems and brain tissue from patients that LRRK2
mutations do not result in large alterations in basal gene expression
under normal growth conditions. These data raise the possibility
that mutant LRRK2 exerts its pathogenic affect through an
alternative mechanism, for example through post translational
Figure 2. Gene expression scatterplot analysis. (A) Uninduced expression state of HEK cells stably transfected with a construct expressing WT
LRRK2 under the control of an inducible promoter (y axis) vs. cells induced for 12 hrs (x axis) and (B) 24 hrs. The same experimental paradigm was
used for pathogenic mutant LRRK2 R1441C (C–D). n = 6 for all groups. Outer lines denote 1.5 fold expression differences. No genes expressed outside
these levels reached significance (p,0.05). (E) Fibroblast expression profile of Control vs. pathogenic mutant LRRK2. WT (y axis, n = 10) and mutant
LRRK2 G2019S (x axis, n = 8). Outer lines denote 1.5 fold expression differences. No genes expressed outside these levels reached significance
(p,0.05) (F–H) Case control comparison of gene expression in brain tissue from G2019S vs iPD (F), G2019S vs control (G) and iPD vs control (H). n = 5
for G2019S and iPD, n = 15 for control. Outer lines denote 1.5 fold expression differences. No genes expressed outside these levels reached
significance (p,0.05).
doi:10.1371/journal.pone.0022489.g002
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modification via its kinase activity or through altered recruitment
of other co-factors to an active enzymatic complex, aspects of the
biology of LRRK2 that are undergoing investigation in a number
of laboratories [23,24].
Acknowledgments
We thank the patients and their families for their involvement in this study,
without which this work would not have been possible. We thank Dr Selina
Wray for critical comments on the manuscript.
Author Contributions
Conceived and designed the experiments: MJD MRC MPvdB PAL.
Performed the experiments: MJD AK AM CM PD AD JZ SH J-WT PAL.
Analyzed the data: MR DR MPvdB PAL. Contributed reagents/
materials/analysis tools: DC JH J-FMM DH AHS BW RB. Wrote the
paper: MJD MPvdB PAL. Analysis of expression data: MR. Isolation of
mRNA from brain samples: AM. Processing of mRNA from brain samples:
DT. Growth and processing of fibroblast samples: PM.
References
1. Dachsel JC, Farrer MJ (2010) LRRK2 and Parkinson disease. Arch Neurol 67:
542–547.
2. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009)
Genome-wide association study reveals genetic risk underlying Parkinson’s
disease. Nat Genet 41: 1308–1312.
3. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. (2009) Genome-wide
association study identifies common variants at four loci as genetic risk factors for
Parkinson’s disease. Nat Genet 41: 1303–1307.
4. Hsu CH, Chan D, Wolozin B (2010) LRRK2 and the stress response: interaction
with MKKs and JNK-interacting proteins. Neurodegener Dis 7: 68–75.
Figure 3. Gene expression dendrograms. (A) Unsupervised cluster analysis. Euclidian clustering of all induced LRRK2 time points (0, 12, 24 hrs)
for WT and RC= R1441C. (B) The same clustering method used for the patient fibroblast expression data. CON=WT, G2019S and R1441G =
pathogenic forms of LRRK2. In each case, separation of the groups was not possible.
doi:10.1371/journal.pone.0022489.g003
Global Gene Expression Analysis of LRRK2 Mutants
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22489
5. Lewis PA (2009) The function of ROCO proteins in health and disease. Biol Cell
101: 183–191.
6. Hsu CH, Chan D, Greggio E, Saha S, Guillily MD, et al. (2010) MKK6 binds
and regulates expression of Parkinson’s disease-related protein LRRK2.
J Neurochem 112: 1593–1604.
7. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, et al. (2008)
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic
neurons in Drosophila. Embo J 27: 2432–2443.
8. Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates
microRNA-mediated translational repression. Nature 466: 637–641.
9. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs
predominantly act to decrease target mRNA levels. Nature 466: 835–840.
10. Sharma S, Bandopadhyay R, Lashley T, Rentom A, Kingsbury A, et al. (2011)
LRRK2 expression in idiopathic and G2019S positive Parkinson’s disease
subjects: a morphological and quantitative study. Neuropathol Appl Neurobiol
epub ahead of press.
11. Sly WS, Grubb J (1979) Isolation of fibroblasts from patients. Methods Enzymol
58: 444–450.
12. Kumar A, Greggio E, Beilina A, Kaganovich A, Chan D, et al. (2010) The
Parkinson’s disease associated LRRK2 exhibits weaker in vitro phosphorylation
of 4E-BP compared to autophosphorylation. PLoS One 5: e8730.
13. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase
activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol
Dis 23: 329–341.
14. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, et al. (2011) Characterization
of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat Chem Biol
7: 203–205.
15. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, et al. (2008) The Sun Health
Research Institute Brain Donation Program: description and experience, 1987-
2007. Cell Tissue Bank 9: 229–245.
16. van der Brug MP, Blackinton J, Chandran J, Hao LY, Lal A, et al. (2008) RNA
binding activity of the recessive parkinsonism protein DJ-1 supports involvement
in multiple cellular pathways. Proc Natl Acad Sci U S A 105: 10244–10249.
17. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The
RIN: an RNA integrity number for assigning integrity values to RNA
measurements. BMC Mol Biol 7: 3.
18. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of
the gene containing mutations that cause PARK8-linked Parkinson’s disease.
Neuron 44: 595–600.
19. Cookson MR, Hardy J, Lewis PA (2008) Genetic neuropathology of Parkinson’s
disease. Int J Clin Exp Pathol 1: 217–231.
20. Mutez E, Larvor L, Lepretre F, Mouroux V, Hamalek D, et al. (2010)
Transcriptional profile of Parkinson blood mononuclear cells with LRRK2
mutation. Neurobiol Aging.
21. Mortiboys H, Johansen KK, Aasly JO, Bandmann O (2010) Mitochondrial
impairment in patients with Parkinson disease with the G2019S mutation in
LRRK2. Neurology 75: 2017–2020.
22. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, et al. (2011) LRRK2
mutant iPSC-derived DA neurons demonstrate increased susceptibility to
oxidative stress. Cell Stem Cell 8: 267–280.
23. Greggio E, Cookson MR (2009) Leucine Rich Repeat Kinase 2 mutations and
Parkinson’s disease: Three Questions. ASN Neuro;doi:10.1042/AN20090007.
24. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in
Parkinson’s disease. Nat Rev Neurosci 11: 791–797.
Global Gene Expression Analysis of LRRK2 Mutants
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22489
